Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more
Immunitybio Inc (IBRX) - Net Assets
Latest net assets as of September 2025: $-50.83 Million USD
Based on the latest financial reports, Immunitybio Inc (IBRX) has net assets worth $-50.83 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($518.99 Million) and total liabilities ($569.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-50.83 Million |
| % of Total Assets | -9.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -237.12% |
| Growth Volatility | 221.05 |
Immunitybio Inc - Net Assets Trend (2013–2024)
This chart illustrates how Immunitybio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Immunitybio Inc (2013–2024)
The table below shows the annual net assets of Immunitybio Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-488.13 Million | +16.69% |
| 2023-12-31 | $-585.94 Million | -30.26% |
| 2022-12-31 | $-449.82 Million | -84.42% |
| 2021-12-31 | $-243.91 Million | -105.85% |
| 2020-12-31 | $-118.49 Million | -198.19% |
| 2019-12-31 | $120.68 Million | -17.35% |
| 2018-12-31 | $146.01 Million | -33.28% |
| 2017-12-31 | $218.84 Million | -25.42% |
| 2016-12-31 | $293.42 Million | -17.58% |
| 2015-12-31 | $356.00 Million | +509.34% |
| 2014-12-31 | $58.42 Million | +2118.07% |
| 2013-12-31 | $-2.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunitybio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 336872000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $85.00K | % |
| Other Comprehensive Income | $1.20 Million | % |
| Other Components | $2.88 Billion | % |
| Total Equity | $-489.10 Million | 100.00% |
Immunitybio Inc Competitors by Market Cap
The table below lists competitors of Immunitybio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marui Group Co. Ltd
F:MUI
|
$2.77 Billion |
|
La Française des Jeux Société anonyme
VI:FDJ
|
$2.77 Billion |
|
Sandfire Resources Limited
PINK:SNDFY
|
$2.77 Billion |
|
Four Corners Property Trust Inc
NYSE:FCPT
|
$2.77 Billion |
|
Zhejiang CFMoto Power Co Ltd
SHG:603129
|
$2.76 Billion |
|
Scotts Miracle-Gro Company
NYSE:SMG
|
$2.76 Billion |
|
HMT(Xiamen)New Technical
SHG:603306
|
$2.76 Billion |
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
$2.76 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunitybio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -586,987,000 to -489,098,000, a change of 97,889,000.
- Net loss of 413,564,000 reduced equity.
- New share issuances of 111,357,000 increased equity.
- Other comprehensive income increased equity by 1,188,000.
- Other factors increased equity by 398,908,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-413.56 Million | -84.56% |
| Share Issuances | $111.36 Million | +22.77% |
| Other Comprehensive Income | $1.19 Million | +0.24% |
| Other Changes | $398.91 Million | +81.56% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Immunitybio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.01 | $8.21 | x |
| 2014-12-31 | $0.19 | $8.21 | x |
| 2015-12-31 | $1.24 | $8.21 | x |
| 2016-12-31 | $0.89 | $8.21 | x |
| 2017-12-31 | $0.68 | $8.21 | x |
| 2018-12-31 | $0.45 | $8.21 | x |
| 2019-12-31 | $0.31 | $8.21 | x |
| 2020-12-31 | $-0.31 | $8.21 | x |
| 2021-12-31 | $-0.62 | $8.21 | x |
| 2022-12-31 | $-1.12 | $8.21 | x |
| 2023-12-31 | $-1.15 | $8.21 | x |
| 2024-12-31 | $-0.70 | $8.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunitybio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2804.77%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-23.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -341.17% | 0.29x | 0.00x | $-1.76 Million |
| 2014 | -10.63% | -969.27% | 0.01x | 1.04x | $-12.06 Million |
| 2015 | -66.54% | -100371.19% | 0.00x | 1.03x | $-272.48 Million |
| 2016 | -41.17% | -274565.91% | 0.00x | 1.08x | $-150.15 Million |
| 2017 | -44.06% | -214273.33% | 0.00x | 1.14x | $-118.31 Million |
| 2018 | -65.91% | -204736.17% | 0.00x | 1.25x | $-110.83 Million |
| 2019 | -54.52% | -152997.67% | 0.00x | 1.19x | $-77.86 Million |
| 2020 | 0.00% | -36669.59% | 0.00x | 0.00x | $-209.87 Million |
| 2021 | 0.00% | -37129.55% | 0.00x | 0.00x | $-322.57 Million |
| 2022 | 0.00% | -173569.58% | 0.00x | 0.00x | $-371.83 Million |
| 2023 | 0.00% | -93761.41% | 0.00x | 0.00x | $-524.50 Million |
| 2024 | 0.00% | -2804.77% | 0.04x | 0.00x | $-364.65 Million |
Industry Comparison
This section compares Immunitybio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunitybio Inc (IBRX) | $-50.83 Million | 0.00% | N/A | $2.76 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |